FCX Q3 Earnings Call Highlights Grasberg Recovery and Growth Plans

Freeport-McMoRan reported adjusted Q3 2026 EPS of $0.88, 10% above the $0.80 consensus, and revenue of $7.55 billion, 6.5% above estimates and up 8.23% year over year. Management targets copper sales above 4 billion pounds by 2028, with Grasberg expected to reach near-full capacity by year-end 2027; leaching initiatives aim to add 300 million pounds annually in 2027. The growth outlook is tempered by reduced 2026 and 2027 sales projections, about $500 million in additional 2026 energy expense, and planned capex of $4.4 billion in 2026 and $5.2 billion in 2027.

Analysis

The equity case is shifting from copper-price leverage toward delivery leverage: if Grasberg volumes recover, fixed costs now weighing on unit economics should be spread over more output, but the lowered sales outlook shows the ramp is not yet bankable. That makes operational milestones—not the earnings beat or laboratory leach results—the key near-term signals. The 2027 production profile is back-half weighted, so early-year results could disappoint investors even if the full-year target remains intact.

The offset is cash conversion. Higher diesel expense and rising capital spending can absorb a meaningful share of incremental operating cash, limiting how much volume growth translates into free cash flow or valuation support. Treat leaching as unpriced optionality until field-scale recoveries and costs are disclosed; extrapolating lab performance to the 2030 aspiration is premature. Bagdad is a longer-dated supply addition, not a near-term earnings catalyst, and approval would add a substantial multi-year capital commitment.

Over the next 1–3 months, monitor the Bagdad decision, mine-plan details and any estimate revisions. Over 6–18 months, Grasberg ramp execution and commercial leach data determine whether FCX earns a volume-growth premium. A broader copper-supply response could also temper commodity upside, even as it benefits FCX’s own production. The bullish thesis weakens if Grasberg misses its stated recovery trajectory, sales guidance is cut again, or unit costs fail to improve as production rises.

Key Decisions for Investors

• Keep FCX as a measured, execution-sensitive long rather than adding solely on the earnings surprise. Consider adding only after the next operating update confirms sequential Grasberg recovery; no price-based entry is supportable from the supplied information.
• Treat the 2027 leach target as a catalyst watch, not base-case production. Reassess after commercial deployment provides field recovery, throughput and cost data; do not underwrite the longer-term aspiration until those results are independently demonstrated.
• Track cash conversion alongside output: flag further increases in capex or energy costs, or failure of unit costs to benefit from higher throughput, as reasons to reduce exposure even if copper sales rise.
• Falsification alerts: another downward sales revision, a missed Grasberg ramp milestone, or materially weaker-than-guided cash generation. Conversely, verified ramp progress with stable cost guidance would support adding on weakness.